GO:0032724 positive regulation of fractalkine production: Immune Regulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032724 describes any process that activates or increases the frequency, rate, or extent of fractalkine (CX3CL1) production.
• Fractalkine is a unique CX3C chemokine that exists in membrane-bound and soluble forms, mediating both adhesion and chemotaxis of CX3CR1-expressing cells.
• Positive regulation of fractalkine production is critical in inflammatory diseases, cancer, and neuroinflammatory conditions [2,7,8].
• Key regulators include pro-inflammatory cytokines such as TNF-alpha, which can upregulate CX3CL1 production in various cell types.
• Dysregulated fractalkine production contributes to rheumatoid arthritis, Huntington's disease, and tumor immune evasion [2,7,8].
• CRISPR-based models (knockout, knock-in, overexpression) enable precise dissection of the regulatory mechanisms controlling fractalkine production [2,4].
Description
Fractalkine (CX3CL1) is a unique chemokine that functions both as a membrane-bound adhesion molecule and as a soluble chemoattractant for CX3CR1-expressing leukocytes. The Gene Ontology term GO:0032724, positive regulation of fractalkine production, encompasses any process that activates or increases the frequency, rate, or extent of fractalkine production. This regulatory process is essential for coordinating immune cell migration and adhesion in inflammatory and homeostatic contexts [4,5]. Understanding how fractalkine production is positively regulated has broad implications for immunology, cancer biology, and neurobiology [2,7,8]. Researchers study this term to identify molecular switches that could be targeted to modulate inflammation or enhance anti-tumor immunity [2,3].
positive regulation of fractalkine production At A Glance
| GO ID | GO:0032724 |
|---|---|
| GO term | positive regulation of fractalkine production |
| Ontology | biological_process |
| Synonym | activation of fractalkine production, stimulation of fractalkine production, up regulation of fractalkine production, up-regulation of fractalkine production, upregulation of fractalkine production |
| Major function | Increases the production of the chemokine fractalkine (CX3CL1), which mediates leukocyte adhesion and chemotaxis. |
| Related chemokine | CX3CL1 (fractalkine) |
| Related receptor | CX3CR1 |
| Cellular context | Endothelial cells, epithelial cells, macrophages, synovial fibroblasts, neurons [5,6,7,8] |
What Is GO:0032724?
GO:0032724 is a biological process term defined as any process that activates or increases the frequency, rate, or extent of fractalkine production. In other words, it covers the upstream signals and molecular events that lead to increased synthesis and secretion of the chemokine CX3CL1 (fractalkine).
Why Is positive regulation of fractalkine production Important in Cell Biology?
Positive regulation of fractalkine production is important because fractalkine is a key mediator of immune cell recruitment and adhesion in both health and disease. Its upregulation is associated with chronic inflammatory conditions such as rheumatoid arthritis and gingival overgrowth, and it can influence tumor immunity by affecting CD8+ T-cell infiltration [1,2,7]. In the brain, fractalkine signaling is critical for microglial-neuronal communication, and reduced fractalkine levels contribute to synaptic plasticity deficits in Huntington's disease. Therefore, understanding how fractalkine production is positively regulated offers therapeutic opportunities for modulating inflammation, cancer, and neurodegeneration [2,3,8].
• Fractalkine upregulation promotes leukocyte adhesion and migration in inflammation.
• TNF-alpha and other pro-inflammatory cytokines can positively regulate fractalkine production.
• Dysregulated fractalkine production is implicated in rheumatoid arthritis synovial fibroblast proliferation.
• In cancer, fractalkine production influences CD8+ T-cell infiltration and anti-tumor immunity.
• Reduced fractalkine levels are linked to synaptic plasticity deficits in Huntington's disease.
• Fractalkine is expressed in endometrium and may play a role in menstrual cycle regulation.
• Toll-like receptor signaling can modulate chemokine production, including fractalkine.
• Fractalkine levels are elevated in gingival overgrowth, suggesting a role in oral inflammatory diseases.
• Myeloid-derived suppressor cell infiltration can be affected by fractalkine regulation.
• CRISPR screening can identify novel regulators of fractalkine production [2,4].
What Happens During positive regulation of fractalkine production?
Initiation by Pro-inflammatory Signals
In simple terms: Inflammation triggers cells to make more fractalkine.
Pro-inflammatory cytokines such as TNF-alpha activate signaling cascades that lead to increased transcription of the CX3CL1 gene. In placental lobules, TNF-alpha production under normoxic and hypoxic conditions correlates with CX3CL1 production, and CX3CR1 signaling further modulates this process. Similarly, Toll-like receptor 2 stimulation in simian immunodeficiency virus-infected macaques can influence chemokine production.
Transcriptional Activation of CX3CL1
In simple terms: Specific transcription factors turn on the fractalkine gene.
Upon stimulation, transcription factors such as NF-kB and STAT proteins are activated and bind to the CX3CL1 promoter, enhancing its transcription. This leads to increased mRNA levels of CX3CL1, as observed in various cell types including endothelial cells and synovial fibroblasts.
Post-transcriptional and Translational Control
In simple terms: The cell fine-tunes how much fractalkine protein is made from the mRNA.
MicroRNAs and RNA-binding proteins can modulate CX3CL1 mRNA stability and translation efficiency. For example, in hepatocellular carcinoma, macrophage DHX34 acts as a negative regulator of the CX3CL1-CX3CR1 axis, suggesting that positive regulation involves overcoming such negative regulators.
Protein Processing and Secretion
In simple terms: Fractalkine is processed and released from the cell surface.
CX3CL1 is synthesized as a type I transmembrane protein. Proteolytic cleavage by metalloproteinases such as ADAM10 and ADAM17 releases the soluble chemokine domain, which can act as a chemoattractant. Positive regulation of fractalkine production can therefore also involve increased shedding or altered trafficking.
Feedback and Amplification Loops
In simple terms: Fractalkine can amplify its own production through feedback.
Soluble fractalkine binding to CX3CR1 on adjacent cells can activate signaling that further enhances CX3CL1 expression, creating a positive feedback loop. This amplification is relevant in chronic inflammatory diseases such as rheumatoid arthritis.
Key Genes Involved in GO:0032724 positive regulation of fractalkine production
The following genes and proteins are directly involved in the positive regulation of fractalkine production, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CX3CL1 | Encodes fractalkine; the target of regulation | Central to all studies of GO:0032724 [1,5] |
| CX3CR1 | Receptor for fractalkine; mediates feedback | Modulates fractalkine production via signaling |
| TNF | Pro-inflammatory cytokine that upregulates CX3CL1 | Key inducer of fractalkine production |
| ADAM10 | Metalloproteinase that cleaves membrane-bound CX3CL1 | Regulates soluble fractalkine release |
| ADAM17 | Metalloproteinase that cleaves membrane-bound CX3CL1 | Regulates soluble fractalkine release |
| NFKB1 | Transcription factor that activates CX3CL1 promoter | Mediates inflammatory induction |
| STAT1 | Transcription factor involved in CX3CL1 expression | Potential regulator |
| DHX34 | RNA helicase; negative regulator of CX3CL1-CX3CR1 axis | Target for enhancing fractalkine production in cancer |
| TLR2 | Toll-like receptor that can modulate chemokine production | Influences fractalkine in infection |
| IL1B | Pro-inflammatory cytokine that may induce CX3CL1 | Potential upstream regulator |
| IFNG | Cytokine that can modulate chemokine production | May affect fractalkine in inflammation |
| CCL2 | Chemokine co-regulated with fractalkine | Marker of inflammatory milieu |
| VEGFA | Angiogenic factor that can induce CX3CL1 | Linked to endothelial fractalkine production |
| MMP2 | Matrix metalloproteinase; may cleave CX3CL1 | Potential sheddase |
| MMP9 | Matrix metalloproteinase; may cleave CX3CL1 | Potential sheddase |
| CD8A | Marker of T cells recruited by fractalkine | Readout of fractalkine function |
| P2RX7 | Purinergic receptor that can trigger chemokine release | Potential regulator in inflammation |
How Is positive regulation of fractalkine production Regulated?
Positive regulation of fractalkine production is controlled at multiple levels. Pro-inflammatory cytokines such as TNF-alpha and IL-1beta activate NF-kB and STAT pathways, leading to increased CX3CL1 transcription. Toll-like receptor signaling, particularly TLR2, can also enhance chemokine production in infectious contexts. Negative regulators such as DHX34 can suppress the CX3CL1-CX3CR1 axis, and their downregulation may contribute to increased fractalkine production in tumors. Additionally, CX3CR1 signaling itself can create a positive feedback loop that amplifies fractalkine production. Post-transcriptional mechanisms, including microRNA-mediated mRNA decay, provide further layers of regulation.
positive regulation of fractalkine production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CX3CL1 | Rheumatoid arthritis | Knockout mouse or synovial fibroblast KO |
| CX3CL1 | Huntington's disease | Striatal neuron overexpression or KO |
| DHX34 | Hepatocellular carcinoma | Macrophage-specific knockout or knockdown |
| CX3CL1 | Gingival overgrowth | Gingival fibroblast overexpression |
| CX3CR1 | Neuroinflammation | CX3CR1 knockout mouse [5,8] |
Rheumatoid Arthritis
In rheumatoid arthritis, fractalkine mediates T cell-dependent proliferation of synovial fibroblasts, contributing to synovial hyperplasia and joint destruction. Positive regulation of fractalkine production in the synovium amplifies inflammatory cell recruitment and fibroblast activation, making it a potential therapeutic target.
Huntington's Disease
Reduced fractalkine levels lead to striatal synaptic plasticity deficits in Huntington's disease models. Positive regulation of fractalkine production may be neuroprotective by maintaining microglial-neuronal communication and synaptic function.
Hepatocellular Carcinoma
Macrophage DHX34 acts as a negative regulator of the CX3CL1-CX3CR1 axis and CD8+ T-cell infiltration in hepatocellular carcinoma. Therefore, positive regulation of fractalkine production could enhance anti-tumor immunity by promoting CD8+ T-cell recruitment.
Gingival Overgrowth
Elevated levels of fractalkine (CX3CL1) and TNF-alpha are observed in gingival crevicular fluid and tissue of patients with gingival overgrowth, suggesting that positive regulation of fractalkine production contributes to oral inflammatory pathology.
From positive regulation of fractalkine production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate fractalkine production? | CRISPR knockout of gene X in relevant cell type |
| Does a point mutation in CX3CL1 affect its secretion? | CRISPR point mutation knock-in |
| Can we tag endogenous CX3CL1 for live imaging? | CRISPR knock-in of fluorescent tag |
| Does overexpression of gene Y increase fractalkine? | CRISPR overexpression (CRISPRa) or lentiviral overexpression |
| Which genes regulate fractalkine production genome-wide? | CRISPR library screening [2,4] |
| Does a disease-associated SNP affect fractalkine levels? | CRISPR knock-in of SNP in cell line |
How to Study the positive regulation of fractalkine production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Identify positive regulators of CX3CL1 |
| CRISPR knock-in | Tagged or mutant protein expression | Track CX3CL1 localization and secretion |
| RNA-seq | Transcriptome changes | Measure CX3CL1 mRNA induction |
| ELISA | Soluble fractalkine protein levels | Quantify production in supernatants |
| Western blot | Membrane-bound and soluble CX3CL1 | Assess processing and shedding |
| Immunofluorescence | Cellular localization of CX3CL1 | Visualize expression in tissues |
| Chemotaxis assay | Functional leukocyte migration | Test biological activity of fractalkine |
| CRISPR library screening | Genome-wide regulators | Discover novel modulators of fractalkine [2,4] |
CRISPR Knockout and Knock-in Models
CRISPR-Cas9 knockout of candidate regulators (e.g., DHX34) can reveal their role in fractalkine production. Knock-in of tags or point mutations allows precise tracking of CX3CL1 expression and secretion.
Transcriptional and Post-transcriptional Profiling
RNA-seq and qPCR can quantify CX3CL1 mRNA levels after stimulation with TNF-alpha or other inducers. Ribo-seq can assess translation efficiency, while microRNA profiling can identify post-transcriptional regulators.
Protein Detection and Imaging
ELISA and Western blot can measure soluble and membrane-bound fractalkine [1,5]. Immunofluorescence and live-cell imaging of tagged CX3CL1 can visualize trafficking and shedding.
Functional Assays
Chemotaxis assays with CX3CR1-expressing cells can measure the functional impact of altered fractalkine production. Co-culture systems with T cells or synovial fibroblasts can model disease-relevant outcomes.
How CRISPR Can Be Used to Study GO:0032724 positive regulation of fractalkine production
Knockout
CRISPR knockout of candidate genes such as DHX34 can determine whether they negatively regulate fractalkine production; loss of a negative regulator leads to increased CX3CL1. Knockout of CX3CL1 itself serves as a control for loss of function.
Point Mutation
Introducing point mutations in the CX3CL1 promoter or coding region can reveal regulatory elements or cleavage sites essential for production and shedding. Disease-associated SNPs can be modeled to assess their impact on fractalkine levels.
Knock-in
Knock-in of fluorescent or epitope tags into the endogenous CX3CL1 locus enables real-time tracking of protein expression, trafficking, and secretion without overexpression artifacts.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of candidate positive regulators can confirm sufficiency for inducing fractalkine production. Overexpression of CX3CL1 itself can model pathological elevation seen in inflammatory diseases [1,7].
How EDITGENE Supports positive regulation of fractalkine production Research
Researchers studying positive regulation of fractalkine production-related genes often need to determine whether a candidate gene is causally involved in CX3CL1 induction, processing, or secretion. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of fractalkine production research.
Frequently Asked Questions About positive regulation of fractalkine production
What is GO:0032724?
GO:0032724 is the Gene Ontology term for positive regulation of fractalkine production, defined as any process that activates or increases the frequency, rate, or extent of fractalkine (CX3CL1) production.
What genes are involved in positive regulation of fractalkine production?
Key genes include CX3CL1 itself, its receptor CX3CR1, pro-inflammatory cytokines like TNF, transcription factors NF-kB and STAT1, and negative regulators such as DHX34 [2,5].
How is fractalkine production regulated?
Fractalkine production is positively regulated by inflammatory signals (e.g., TNF-alpha) that activate transcription factors, and negatively regulated by RNA helicases like DHX34; post-transcriptional mechanisms also play a role [2,5].
What diseases are associated with fractalkine overproduction?
Fractalkine overproduction is linked to rheumatoid arthritis, gingival overgrowth, and certain cancers, where it can promote inflammation or immune evasion [1,2,7].
Can CRISPR be used to study fractalkine production?
Yes, CRISPR knockout, knock-in, and overexpression models allow precise manipulation of candidate genes to test their effects on fractalkine production [2,5].
What is the role of CX3CL1 in cancer?
CX3CL1 (fractalkine) can recruit CD8+ T cells to tumors; its positive regulation may enhance anti-tumor immunity, while negative regulators like DHX34 suppress it.
How do I measure fractalkine production?
Fractalkine production can be measured by ELISA, Western blot, RNA-seq, and functional chemotaxis assays [1,5].
What cell types produce fractalkine?
Fractalkine is produced by endothelial cells, epithelial cells, macrophages, synovial fibroblasts, and neurons, among others [5,6,7,8].
Is fractalkine production increased in Huntington's disease?
In Huntington's disease models, reduced fractalkine levels are observed, suggesting that positive regulation may be neuroprotective.
What CRISPR services does EDITGENE offer for fractalkine research?
EDITGENE offers knockout, point mutation, knock-in, overexpression, CRISPR library screening, and bioinformatics services to study fractalkine regulation [2,4].
Conclusion
Positive regulation of fractalkine production (GO:0032724) is a critical biological process that controls the levels of the chemokine CX3CL1, influencing immune cell recruitment, inflammation, and neuronal function [5,8]. Dysregulation of this process contributes to diseases such as rheumatoid arthritis, cancer, and Huntington's disease [2,7,8]. By leveraging CRISPR-based models and advanced screening technologies, researchers can uncover the molecular mechanisms that positively regulate fractalkine production, paving the way for novel therapeutic strategies [2,4].
References
- 1. Hamurcu N et al.. 2025. Evaluation of the levels of Fractalkine (CX3CL1), TNF-α, and TGF-β in the gingival crevicular fluid/tissue of patients with gingival overgrowth: a cross-sectional observational study.. J Appl Oral Sci 33:e20250304 PMID: 41337567
- 2. Li Z et al.. 2026. Macrophage DHX34 as a negative regulator of the CX3CL1-CX3CR1 axis and CD8(+) T-cell infiltration in hepatocellular carcinoma.. Int Immunopharmacol 169:116014 PMID: 41389669
- 3. Yokota S et al.. 2025. Sorafenib inhibits myeloid-derived suppressor cell infiltration in canine transitional cell carcinoma.. Vet Immunol Immunopathol 290:111019 PMID: 41175664
- 4. Boby N et al.. 2023. Toll-like Receptor 2 Mediated Immune Regulation in Simian Immunodeficiency Virus-Infected Rhesus Macaques.. Vaccines (Basel) 11(12) PMID: 38140264
- 5. Szukiewicz D et al.. 2014. CX3CL1 (fractalkine) and TNFα production by perfused human placental lobules under normoxic and hypoxic conditions in vitro: the importance of CX3CR1 signaling.. Inflamm Res 63(3):179-89 PMID: 24270813
- 6. Watanabe M et al.. 2006. The expression of fractalkine in the endometrium during the menstrual cycle.. Int J Gynaecol Obstet 92(3):242-7 PMID: 16430900
- 7. Sawai H et al.. 2007. Fractalkine mediates T cell-dependent proliferation of synovial fibroblasts in rheumatoid arthritis.. Arthritis Rheum 56(10):3215-25 PMID: 17907166
- 8. Kim A et al.. 2020. Reduced Fractalkine Levels Lead to Striatal Synaptic Plasticity Deficits in Huntington's Disease.. Front Cell Neurosci 14:163 PMID: 32625064
